Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Operating expenses:
Research and development	$ 252		$ 732	$ 28,927
General and administrative	96,330	238,758	263,071	436,958
Goodwill impairment (See note 2 and 3)		6,083,146		6,083,146
Total operating expenses	96,582	6,321,904	263,803	6,549,031
Loss from operations	(96,582)	(6,321,904)	(263,803)	(6,549,031)
Other income (expense):
Interest expense, net	(215,619)	(257,396)	(450,330)	(651,675)
Reimbursement for expenses - related party	10,398		22,937	72,246
Change in fair value of derivative on debt	23,630	(307,698)	26,106	(327,594)
Loss on extinguishment / conversion of debt			(88,258)
Miscellaneous income		36,988
Total other income (expense)	(181,591)	(528,106)	(489,545)	(907,023)
Net income (loss) before non-controlling interests	(278,173)	(6,850,010)	(753,348)	(7,456,054)
Net income (loss) attributable to non-controlling interests	(68,336)	(93,010)	(134,835)	(173,635)
Net income (loss) attributable to Oncotelic Therapeutics, Inc.	$ (209,837)	$ (6,757,000)	$ (618,513)	$ (7,282,419)
Basic net income (loss) per share attributable to common stock	$ (0.00)	$ (0.02)	$ (0.00)	$ (0.02)
Basic weighted average common stock outstanding	401,595,958	394,374,227	401,487,247	393,829,610